2,165 reports of this reaction
4.2% of all SORAFENIB reports
#2 most reported adverse reaction
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is the #2 most commonly reported adverse reaction for SORAFENIB, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 2,165 FDA adverse event reports linking SORAFENIB to PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME. This represents approximately 4.2% of all 51,866 adverse event reports for this drug.
Patients taking SORAFENIB who experience palmar plantar erythrodysaesthesia syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is moderately reported among SORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to palmar plantar erythrodysaesthesia syndrome, the following adverse reactions have been reported for SORAFENIB:
The following drugs have also been linked to palmar plantar erythrodysaesthesia syndrome in FDA adverse event reports:
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME has been reported as an adverse event in 2,165 FDA reports for SORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME accounts for approximately 4.2% of all adverse event reports for SORAFENIB, making it one of the most commonly reported side effect.
If you experience palmar plantar erythrodysaesthesia syndrome while taking SORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.